This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Investigator
- Ali Ataya
- Ages
- 18 Years - 75 Years
- Sexes
- All
Clinical trials
-
GB002-3102 -
United therapeutics 301 Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)…
- Investigator
- Ali Ataya
- Ages
- 18 Years - N/A
- Sexes
- All